Treatment of male pattern baldness in men (androgenetic alopecia) to increase hair growth and prevent further loss.
Composition:
1 tabl powl. contains 1 mg finasteride.
Action:
A competitive and specific inhibitor of Type II 5-α-reductase, an enzyme involved in testosterone metabolism. Inhibition of this enzyme blocks the peripheral conversion of testosterone to 5-α-dihydrotestosterone (DHT), which is the hormone responsible for the male pattern balding process (androgenetic alopecia). Finasteride has no affinity for the androgen receptor, it has no androgenic, antiandrogenic, estrogenic, antiestrogenic or progestagenic effects. The oral bioavailability of finasteride is approximately 80% and is independent of food (C.max in the blood reaches after 2 h after administration). Approximately 93% of the drug is bound to plasma proteins. Finasteride is metabolised in the liver (CYP 3A4) and excreted in the faeces and urine. Application of the preparation leads to a rapid (within 24 h) reduction of DHT concentration in the blood, and consequently - also in tissues, including in the scalp. The process of miniaturization of hair follicles, occurring in the course of male pattern baldness, is also inhibited, which results in the reversal of the process of baldness and increased hair growth. The preparation has the highest effectiveness in men with mild and moderate hair loss, whereas it has no therapeutic effect in women with androgenetic alopecia.
Contraindications:
Hypersensitivity to finasteride or other ingredients. Co-administration of finasteride or other 5α-type reductase inhibitors in the treatment of benign prostatic hyperplasia or other diseases. Do not use in women and children.
Precautions:
It should not be used in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose. There are no data showing the efficacy or safety of finasteride in children under 18 years of age.
Pregnancy and lactation:
The use of the drug in pregnant women, breastfeeding or in childbearing age is contraindicated. In addition, pregnant women and women of childbearing age should not touch crushed or damaged tablets due to the possibility of percutaneous absorption of finasteride and the resulting risk to the male fetus.
Side effects:
Uncommon: decreased libido, erectile dysfunction, ejaculation disorders (including decreased ejaculate volume). Not known: hypersensitivity reactions including rash, pruritus, urticaria and swelling of the lips and face, palpitations, increased liver enzymes, tenderness and enlargement of the mammary glands, testicular pain, infertility. In addition: persistence of erectile dysfunction after discontinuation of treatment, breast cancer in men.
Dosage:
Oral: 1 tablet once a day. The drug should be taken during or without meals. The minimum treatment period is 3 months, but it is recommended to use the preparation continuously, because after its withdrawal, the therapeutic effect achieved disappears within 9-12 months. There is no need to change the dosage in patients with renal insufficiency.
(C)
